This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nuermberger, E.
Right arrow Articles by Grosset, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nuermberger, E.
Right arrow Articles by Grosset, J. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1522-1524, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.00074-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis{triangledown}

Eric Nuermberger,* Sandeep Tyagi, Rokeya Tasneen, Kathy N. Williams, Deepak Almeida, Ian Rosenthal, and Jacques H. Grosset

Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland

Received 17 January 2008/ Returned for modification 20 January 2008/ Accepted 6 February 2008

PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

* Corresponding author. Mailing address: 1550 Orleans St., Baltimore, MD 21231-1002. Phone: (410) 502-0580. Fax: (410) 614-8173. E-mail: enuermb{at}jhmi.edu

{triangledown} Published ahead of print on 19 February 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1522-1524, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.00074-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Williams, K. N., Brickner, S. J., Stover, C. K., Zhu, T., Ogden, A., Tasneen, R., Tyagi, S., Grosset, J. H., Nuermberger, E. L. (2009). Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 180: 371-376 [Abstract] [Full Text]  
  • Sung, J. C., Garcia-Contreras, L., VerBerkmoes, J. L., Peloquin, C. A., Elbert, K. J., Hickey, A. J., Edwards, D. A. (2009). Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation. Antimicrob. Agents Chemother. 53: 1338-1343 [Abstract] [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Yew, W. W., Leung, C. C. (2009). Update in Tuberculosis 2008. Am. J. Respir. Crit. Care Med. 179: 337-343 [Full Text]  
  • Guy, E. S., Mallampalli, A. (2008). Review: Managing TB in the 21st century: existing and novel drug therapies. Ther Adv Respir Dis 2: 401-408 [Abstract]  
  • Dharmadhikari, A. S., Nardell, E. A. (2008). What Animal Models Teach Humans about Tuberculosis. Am. J. Respir. Cell Mol. Bio. 39: 503-508 [Abstract] [Full Text]  
  • Tasneen, R., Tyagi, S., Williams, K., Grosset, J., Nuermberger, E. (2008). Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother. 52: 3664-3668 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»